West Pharmaceutical Services, Inc. WST NYSE

West Pharmaceutical Services, Inc. (WST) generated $754.8M in operating cash flow for fiscal year 2025. After capital expenditures of $285.9M, free cash flow was $468.9M.

Free cash flow margin was 15.3% of revenue. Cash conversion ratio was 1.53x, indicating earnings are backed by cash.

The company returned $61.2M in dividends and $134M in share buybacks to shareholders during the period.

Criteria supported by this page:

• HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (57/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (70/100) — Cash conversion ratio was 1.53x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 66/100 with 4/7 criteria passed.